kidney stones and semaglutide Can GLP‑1 medications increase stone risk? A UAB urologist offers insight Cardio-kidney-metabolic protective effects of semaglutide

Since these medications have established safety profiles in approved metabolic indications, researchers feel they could potentially be repurposed for addiction treatment more quickly than entirely new drugs, although safety and tolerability in people with alcohol or substance use disorders still require dedicated testing

Digital tools for dose verification Technology can eliminate calculation errors if you use the right tools correctly

Abbott met EPS estimates at $1.30

Mechanisms by which glucagon-like-Peptide-1 receptor agonists and sodium-glucose Cotransporter-2 inhibitors reduce Cardiovascular risk in adults with type 2 diabetes Mellitus